ArticleHuman vaccines & immunotherapeutics2023

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine.

Xiaolan Yong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.